It is well documented that prolactin (PRL) release and PRL gene expression in birds are controlled by the tonic stimulation of hypothalamic vasoactive intestinal peptide (VIP). However, there is good evidence that dopamine (DA) exerts both stimulatory (at the hypothalamic level) and inhibitory (at the pituitary level) effects on PRL secretion. The interactions between VIP and DA in the regulation of PRL gene transcription are not known. This study was designed to examine the effects of a D 2 DA receptor agonist (D 2 AG; R(−)-propylnorapomorphine HCl) on basal and VIP-stimulated PRL gene transcription rate, PRL mRNA steady-state levels, PRL mRNA stability and PRL release from cultured turkey anterior pituitary cells. The D 2 AG (10 −10 M) completely inhibited the stimulatory effect of VIP (10 −7 M) upon nascent PRL mRNA as determined utilizing a nuclear run-on transcription assay. To examine further the effect of the D 2 AG on PRL mRNA post-transcriptional events, anterior pituitary cells were treated with different concentrations of D 2 AG (10 −12 -10 −4 M). Semi-quantitative RT-PCR and RIA were performed to determine the levels of PRL mRNA and PRL content in the medium respectively. The results show that D 2 AG inhibited VIP-stimulated PRL mRNA steady-state levels as well as basal and VIP-stimulated PRL release, effects which were diminished by the D 2 DA receptor antagonist, S(−)-eticlopride HCl (10 −10 M). Actinomycin D (5 µg/ml), an inhibitor of mRNA synthesis, was used to assess the effect of D 2 AG on PRL mRNA stability in response to VIP. The stimulatory effect of VIP on PRL mRNA stability was completely negated by the D 2 AG (from a half-life of 53·0±2·3 h in VIP-treated cells to 25·5±1·6 h in D 2 AG+VIP-treated cells, P≤0·05). These results support the hypothesis that VIP and DA play a major role in the regulation of PRL gene expression in avian species, at both the transcriptional and post-transcriptional levels. In addition, these findings suggest that the DAergic system inhibits PRL release and synthesis by antagonizing VIP at the pituitary level via D 2 DA receptors.
Introduction
It has been established for some time that prolactin (PRL) secretion in avian species is under tonic stimulatory control exerted by the hypothalamus (Kragt & Meites 1965 , Bern & Nicoll 1968 and several lines of evidence indicate that vasoactive intestinal peptide (VIP) is the PRL-releasing factor (PRF) in birds (for review see El Halawani et al. 1997) . In contrast to birds, the identity of the physiological PRF in mammals remains unascertained (Ben-Jonathan et al. 1989 , Freeman et al. 2000 , Taylor & Samson 2001 . A group of factors, mostly neuropeptides, have been shown to exhibit stimulatory effects on PRL release. Among them are thyrotropin-releasing hormone (TRH) (Curlewis et al. 2002 , Kanasaki et al. 2002 , Yuan & Pan 2002 ) and the newly described PRL-releasing peptides (Hinuma et al. 1998 , Curlewis et al. 2002 . However, PRL release from the anterior pituitary is regulated principally by inhibitory influences imparted by the tuberoinfundibular dopamine (DA) system (Ben-Jonathan et al. 1977 , Pasqualini et al. 1988 , Ben-Jonathan & Hnasko 2001 . In avian species, the role of DA in regulating PRL secretion is still largely obscure. DA, or the DA agonist, apomorphine, reduces PRL secretion caused by the co-incubation of chicken and pigeon pituitary glands with hypothalamic extract, an effect which is reversed by the DA receptor antagonist pimozide (Hall & Chadwick 1983) . In the chicken, DA inhibits the release of PRL stimulated by TRH, hypothalamic extract, or by previous exposure of the pituitary gland to estrogen (Hall & Chadwick 1984) . Specific DA-binding sites identified in the anterior pituitary are found to be more abundant in laying than in incubating hens (Macnamee & Sharp 1989) . Moreover, in cultured turkey pituitary cells, D 2 DA receptor agonists (D 2 AGs) inhibit VIP-stimulated PRL release and PRL mRNA steady-state levels (Xu et al. 1996) . Data from in vivo studies suggest that DA has both stimulatory and inhibitory effects on turkey PRL secretion (Youngren et al. 1995 (Youngren et al. , 1996b . The presence of both D 1 and D 2 DA receptor mRNA in the turkey brain and pituitary (Schnell et al. 1999 , Chaiseha et al. 2003 suggests that DA may exhibit biphasic actions within the turkey hypothalamus and pituitary gland. DA appears to regulate PRL secretion centrally through stimulatory D 1 and inhibitory D 2 DA receptors, while at the pituitary level it exhibits an inhibitory effect on PRL secretion induced by VIP or electrical stimulation (Youngren et al. 1998) .
DA plays an intermediary role in PRL secretion, requiring an intact VIPergic system in order to release PRL (Youngren et al. 1996b) . Dynorphin, serotonin, DA and VIP all appear to stimulate avian PRL secretion along a pathway expressing -opioid, serotonergic, DAergic, and VIPergic receptors at synapses arranged serially in that functional order, with the VIPergic system as the final mediator (for review see El Halawani et al. 2000) . The anatomical distribution of the avian DAergic system apparently resembles that of mammals (Moons et al. 1994) , as DA neurons are found throughout the avian hypothalamus (Kiss & Peczely 1987 , Reiner et al. 1994 , Al-Zailaie & El Halawani 2000 .
The tripeptide hypothalamic-releasing factor, TRH, and the avian PRF, VIP, produce a stimulation of PRL transcription (Camper et al. 1985 , Tong et al. 1998 , and DA effects a transcriptional repression of the PRL gene in cultured rat anterior cell lines (Elsholtz et al. 1991 , Fischberg & Bancroft 1995 . However, the combined effects of these factors on PRL gene (B) Relative quantification of PRL mRNA levels, which were normalized by endogenous β-actin mRNA levels. Values (means±S.E.M., n=6) of three different experiments, with two replicates per treatment were expressed as fold changes from vehicle-treated control (basal) values, which were assigned a value of 1·0. (C) Dose-dependent inhibition of basal and VIPstimulated PRL release by the D 2 AG (n=6). Significant differences (P<0·05) are identified by different letters.
transcription remain largely unexplored. The aims of the present study were: (i) to investigate the interaction between VIP and DA in regulating PRL gene transcription rate, using the nuclear run-on (NRO) transcription assay, and (ii) to explore further the effects of VIP/DA on PRL mRNA steady-state levels, PRL mRNA stability (half-life), and PRL release from cultured turkey primary pituitary cells. This study will attempt to provide further understanding of the interplay between VIP and DA and of their roles in the modulation of PRL secretion and gene transcription in birds.
Materials and methods

Experimental animals
Adult large white female Nicholas turkeys (weighing 10-13 kg) were used in these series of experiments. They were reared and housed on a 15 h light:9 h darkness lighting regimen in temperature-controlled (15-21 C) floor pens, with food and water continuously available. All hens used were laying eggs (Youngren et al. 1996a) . All hens were housed, handled and used in accordance with University of Minnesota Institutional Animal Care and Use Committee Guidelines.
Pituitary tissue collection and cell dispersion
Pituitary glands were collected from decapitated laying turkeys. The posterior lobes of the pituitary glands were removed, and the anterior lobes were dissociated using a modification of the trypsin/ neuraminidase procedure described by Hopkins & Farquhar (1973) . They were minced and replaced in Krebs-Ringer bicarbonate buffer solution (KRB, pH 7·4) supplemented with amino acids (MEM Eagle essential amino acids; BioWhittaker, Walkersville, MD, USA), 0·3 µg/ml glutamine sulfate (Sigma Chemical Co., St Louis, MO, USA), 2·5 mg/ml glucose (Sigma), 3 mg/ml BSA (fraction V, Sigma), and 100 µg/ml gentamycin sulfate (Sigma). Following mechanical shearing, pituitary fragments were digested enzymatically with 1 mg/ml trypsin (Sigma) and 2 µg/ml deoxyribonulease I (DNase I, Sigma) in KRB solution for 15 min at 37 C in a shaking water bath. The supernatant was removed and replaced by a Ca 2+ /Mg 2+ -free supplemented KRB solution containing 2 mM EDTA, disodium salt (Sigma). After 5 min of incubation at 37 C, the supernatant was removed and replaced by a Ca 2+ /Mg 2+ -free supplemented KRB solution containing 1 mM EDTA and 8 µg/ml neuraminidase (Sigma). After 15 min of incubation at 37 C, the pituitary fragments were mechanically dispersed and the resultant cell suspension was filtered through 60 µm mesh Nitex gauze (Genson Scientific, Middleboro, MA, USA) to remove undigested particles. Following centrifugation at 250-500 g for 15 min, the supernatant was decanted and the cell pellet was resuspended in tissue culture medium consisting of medium M-199 (Life Technologies, Rockville, MD, USA) supplemented with 0·35 µg/ ml NaHCO 3, 3% charcoal-stripped turkey poult serum, 3% fetal calf serum (Sigma), 4·8 µg/ml Hepes (Sigma), 1 µg/ml insulin (Sigma), 50 µg/ml gentamycin sulfate (Sigma), 100 U/ml penicillin (Sigma), 100 µg/ml streptomycin (Sigma) and 5 µg/ml amphotericin B (Sigma). Cell viability (90-95%) was determined using the trypan blue dye exclusion and cell numbers were counted in a hemocytometer. The dispersed cells were initially incubated for 72 h in siliconized Erlenmeyer flasks at 38·5 C in humidified atmosphere (95% O 2 and 5% CO 2 ) before conducting the experiments. After preincubation, cultured pituitary cells were pelleted and resuspended in a serum-free M-199 medium (Life Technologies) supplemented with 0·1% BSA.
Pituitary nuclei isolation
Pituitary nuclei were isolated as previously described (Tong et al. 1998 ) with slight modifications. Briefly, pituitary cells were harvested by centrifugation and washed with diethylpyrocarbonate-treated PBS. Nuclei were isolated by incubating the cells for 5 min on ice in a lysing buffer containing 50 mM Tris-HCl, 140 mM NaCl, 1 mM MgCl 2 , 1 mM dithiothreitol (DTT) and 0·5% Nonidet P-40, followed by centrifugation at 1000 g. The nuclei were resuspended in a nuclear freezing buffer (50 mM Tris-HCl, pH 8·3, 5 mM MgCl 2 , 1 mM DTT and 50% glycerol), snap frozen in liquid nitrogen, and stored at -80 C in aliquots of 10 10 6 nuclei/100 µl until the NRO transcription assays were performed. The total cytoplasmic RNA in the supernatant was extracted by a commercial modification of the phenol-chloroform alcohol extraction method (RNeasy Mini Kit system; Qiagen Inc., Valencia, CA, USA) and stored at 80 C until used for semi-quantitative RT-PCR analysis.
NRO transcription assay
The NRO transcription assay was performed by combining several techniques from previously described methods (Preston et al. 1990 , Delidow et al. 1991 . In brief, nuclei were thawed on ice. The in vitro transcription reaction contained 10 10 6 nuclei in a mix of transcription buffer (100 mM Tris-HCl, pH 8·0, 5 mM MgCl 2 , 300 mM KCl, 0·5 mM each of ATP, CTP and GTP, 150 µCi [ -32 P]UTP (NEN Life Science, Boston, MA, USA), 10 mM DTT, and 200 U ribonuclease inhibitor (RNAsin; Promega, Madison, WI, USA)) for 45 min at 26 C. The reaction was terminated by adding 20 U of RNase-free DNase I (Promega) at 37 C for 15 min. The nuclei were then deproteinized by the addition of protein kinase K (200 µg/ml, Sigma) for 30 min at 37 C. Unincorporated nucleotides were removed using the Quick Spin Columns system (Boehringer Mannheim, Indianapolis, IN, USA). Newly synthesized RNA transcripts were isolated using the total RNA isolation protocol (RNeasy Mini Kit system; Qiagen). The labeled PRL, luteinizing hormone (LH)-and -actin mRNA were quantified by hybridization to the PCR-synthesized turkey PRL, -actin and LH-cDNA, and the full-length plasmid vector (Ptz 18R), which was previously immobilized (2 µg/well) onto a Nytran membrane (ISCBioExpress, Kaysville, WT, USA) employing the described slot blot procedure (Ausubel et al. 1989 ). -Actin cDNA and Ptz 18R vector DNA served as positive and negative controls respectively. Blots were prehybridized for 4 h at 42 C in hybridization buffer (50% formamide, 5 standard saline citrate (SSC), 1% SDS, 7 Denhart's solution, 100 µg/ml salmon sperm DNA (Sigma) and 50 µg/ml yeast tRNA (Sigma)). Equal counts of radioactive elongated RNA (0·7-1 10 6 c.p.m.) were then added to the blots and hybridized for 72 h at 42 C. After hybridization, the membranes were washed twice at room temperature for 15 min in 2 SSC and 0·1% SDS, and three times at 65 C for 20 min in 0·1 SSC and 0·1% SDS. Membranes were then air-dried and exposed to Kodak X-ray film (Eastman Kodak, Rochester, NY, USA) at 80 C with the use of intensifying screen to minimize the time of exposure. Autoradiographic densities were quantified using NIH Image-J software (NIH, Bethesda, MD, USA).
RNA extraction and semi-quantitative RT-PCR
Total RNA was extracted from cultured pituitary cells using Trizol reagent (Gibco BRL, MD, USA) as recommended by the manufacturer with minor modifications. To reduce genomic DNA contamination, total RNA was treated with RNase-free DNase I (1 U/µg RNA) for 30 min at 37 C. After DNA digestion, total RNA was re-extracted using the total RNA isolation protocol (RNeasy Mini Kit system) and then RNA concentration was determined using a DU Series 500 spectrophotometer (Beckman, CA, USA). Total RNA (250 ng) was reverse-transcripted using SuperScript II reverse transcriptase and Oligo dT 12-18 primers (Life Technologies) in a reaction volume of 20 µl containing reverse transcriptase buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl 2 , pH 8·4), 10 mM DTT, 0·5 mM of each dNTP, RNase inhibitor (RNAsin), 2·5 mM Oligo dT [12] [13] [14] [15] [16] [17] [18] , and Superscript II TR (200 U), and then incubated at 42 C for 1 h. The reaction was terminated by heating at 70 C for 15 min. Aliquots (2 µl) of the resultant cDNA were used for the PCR reaction, which was performed in a 25 µl volume containing 200 µM of each dNTP, 50 mM KCl, 10 mM Tris-HCl, pH 8·3, 2 mM MgCl 2 , 100 ng genespecific sense and anti-sense primers, and 2·5 U Ampli Taq DNA polymerase (Perkin Elmer, Norwalk, CT, USA). PCR profile consisted of an initial denaturation (30 min, 94 C) followed by cycles of denaturation (1 min, 94 C), annealing (45 s, 60 C), extension (1 min, 72 C), and a final extension for one cycle (10 min, 72 C). The number of amplification cycles was 20-22 for PRL and 30 for -actin, which were within the linear range of amplification. Primer sequences were as follows: PRL (sense, 5 -ACC TCC TTG CCA ATC TGC TCC AGT-3 ; anti-sense, 5 -GGA GTC CTC ATC AGC GAG TTG CAG-3 ; expected size of the PCR product, 523 bp), and -actin (sense, 5 -ACC AGT AAT TGG TAC CGG CTC CTC-3 ; anti-sense, 5 -TCT GGT GGT ACC ACA ATG TAC CCT-3 ; expected size of the PCR product, 450 bp). RT-PCR products were separated in 2% (2:1) agarose and NuSieve GTG gel (FMC Bioproducts, Rockland, ME, USA) and visualized with ethidium bromide. The gels were photographed and the intensities of the PCR products were quantified using NIH Image-J software. To correct for differences in RNA used in RT-PCR reactions, the band intensity for each RT-PCR product of PRL was normalized to that of -actin from the same sample.
PRL RIA
Culture media were assayed for PRL content utilizing the homologous RIA described by Proudman & Opel (1981) . All samples from the same experiment were assayed simultaneously. All samples from each experiment were assayed in duplicate within a single assay.
Drugs
The drugs used were: R( )-propylnorapomorphine HCl, a D 2 AG, (+)-SKF-38393, a D 1 AG, and S( )-eticlopride HCl, a D 2 DA receptor antagonist (Research Biochemicals International, Natick, MA, USA), chicken VIP (cVIP) (Peninsula Laboratory, San Carlos, CA, USA) and actinomycin D (Sigma).
Statistical analysis
The data from RIA, NRO assay and RT-PCR were analyzed using the general linear models , 10 4 M, P,0·05, Fig. 1A 4 M). Semi-quantitative RT-PCR analysis showed that the D 1 AG had no effect on basal or VIP-stimulated PRL mRNA in cultured pituitary cells (P.0·05, Fig. 2A and B) . Basal and VIP-stimulated PRL release were not affected by the different concentrations of D 1 AG added to the pituitary cells (P.0·05, Fig. 2C ).
Experiment 3: inhibitory effects of D 2 AG on VIP-stimulated PRL mRNA levels and PRL release in turkey primary cultured pituitary cells
The D 2 DA receptor antagonist had no effect on basal or VIP-stimulated PRL mRNA levels and PRL release in pituitary cells. However, when the D 2 DA receptor antagonist was added to the cultured pituitary cells 15 min prior to the D 2 AG, it significantly antagonized the inhibitory effect of the D 2 AG on VIP-stimulated PRL mRNA levels (P,0·05, Fig. 3A and B) . Basal and VIP-stimulated PRL release were not inhibited by the D 2 AG when the pituitary cells were preincubated with the D 2 DA receptor antagonist (P.0·05, Fig. 3C ). The D 2 DA receptor antagonist per se had no effect on basal or VIP-stimulated PRL release. The effect of VIP and/or the D 2 AG on PRL mRNA stability in cultured pituitary cells was determined by measuring the half-life (t 1/2 ) of PRL mRNA, which was calculated by statistical regression of the data. VIP (10 7 M) significantly enhanced PRL mRNA stability (t 1/2 =53·0 h) compared with that in non-treated control cells (t 1/2 =26·3 h) and in agonist-treated cells (t 1/2 = 23·6 h) (P,0·05, Fig. 4A and B) . Preincubating pituitary cells with the D 2 AG resulted in a significant reduction in PRL mRNA half-life (t 1/2 = 25·5 h) in VIP-treated pituitary cells (P,0·01). The D 2 AG had no effect on basal PRL mRNA t 1/2 (23·6 h). In non-actinomycin-treated control cells, PRL mRNA t 1/2 did not change throughout the experiment time course (data not shown). Fig. 5A and B) . Preincubation of pituitary cells with the D 2 AG significantly reduced the stimulatory effect of VIP on nascent PRL mRNA (P,0·05). Nascent PRL mRNA was not altered (P.0·05) by the treatment of pituitary cells with the agonist alone. Nascent LH-and -actin mRNA were not affected by the D 2 AG or VIP. Similar to the nascent PRL mRNA, cytoplasmic PRL mRNA steady-state level was 2·5-fold higher in VIP-stimulated pituitary cells than that of non-treated control cells (P,0·05, Fig.  5D1 and D2). The D 2 AG significantly decreased the VIP stimulatory effect on PRL mRNA level (P,0·05). Basal and VIP-stimulated PRL release into the medium was reduced by the addition of the D 2 AG to the incubating medium (P,0·05, Fig. 5C ).
Discussion
The present results show, for the first time in birds, that DA regulates PRL synthesis in cultured primary anterior pituitary cells. DA does this, in part, by antagonizing VIP-stimulated PRL gene transcription via D 2 DA receptors. The results also show that a D 2 AG reduces VIP-stimulated PRL mRNA steady-state level, PRL mRNA half-life, and PRL release at the pituitary level.
The avian PRF, VIP, is a potent stimulator of PRL release and PRL gene expression, both in vivo and in vitro (Macnamee et al. 1986 , Opel & Proudman 1988 , El Halawani et al. 1990a ,b, Xu et al. 1996 . Conversely, as in the present study, D 2 AGs have been shown to inhibit VIP-stimulated PRL mRNA steady-state levels and PRL secretion by turkey pituitary cells (Xu et al. 1996) . Our results show that VIP treatment increased PRL release into the medium by about 20-to 30-fold in comparison with that of untreated pituitary cells. In addition, the D 2 AG, R( )-propylnorapomorphine, inhibited the basal and VIPstimulated PRL release in a dose-dependent manner. However, PRL mRNA steady-state level responded differently to the action of the D 2 AG. The agonist had no effect on basal PRL mRNA levels and its effect on VIP-stimulated PRL mRNA appeared to be all or none. Two possibilities may explain the differences in the PRL secretion mechanism(s) in its response to DA: (i) PRL gene expression may be more sensitive to the inhibitory effect of DA than PRL release -lower concentrations of the agonist than the ones used in the present study might show a dose-response effect, if it exists; alternatively (ii) circulating PRL levels may be fine-tuned by the relative activity of the inhibitory and stimulatory influences of DA on PRL release (Youngren et al. 1995 (Youngren et al. , 1996b , since PRL release is under tonic stimulation by VIP (El Halawani et al. 1997) . This latter possibility may also explain the findings that activation of D 2 DA receptors inhibited basal PRL release, whereas it had no effect on basal PRL mRNA levels.
Changes in PRL mRNA levels can occur because of changes in transcription and/or post-transcription events. The present results show that the D 2 AG, R( )-propylnorapomorphine, significantly inhibited the stimulatory effect of VIP on PRL mRNA at the transcriptional level. Previous studies in mammals have demonstrated the involvement of the pituitary-specific transcription factor (Pit-1, GHF-1) in the hormonal regulation of PRL transcriptional activity, including the inhibitory response to DA (Iverson et al. 1990 , Elsholtz et al. 1991 . Recent work shows that the inhibition of PRL gene transcription by DA is conferred by proximal promoter sequences and that binding sites for Pit-1 are important in this response (Elsholtz et al. 1991 , Lew et al. 1994 . A conserved consensus Pit-1-binding site has been proposed in the avian and teleost PRL/growth hormone gene family (Ohkubo et al. 1996) . Pit-1 cDNA has been cloned in the turkey (Wong et al. 1992 , Kurima et al. 1998 ) and chicken (Tanaka et al. 1999) .
These findings, taken together with the results of the present study, suggest that the inhibitory effect of DA on VIP-induced PRL gene transcription may result from DA suppression of the transactivating function of Pit-1, which is mediated by a pertussis toxin-sensitive G protein, especially G o or G i 2 . The major transactivating domain of mammalian Pit-1 has been localized to the N-terminal region and found to be suppressed by DA (Lew & Elsholtz 1995) . Studying the structure and transcription-initiating mechanism of the chicken PRL gene indicates the involvement of Pit-1 and cAMP in the activation of PRL gene expression (Ohkubo et al. 2000) . However, such a suggestion must be taken with caution as the results of a recent study revealed the absence of Pit-1 protein in turkey lactotrophs (Weatherly et al. 2001) .
The inhibition of transcription rate by DA was not the only determinant of the inhibitory effect of DA on the steady-state levels of PRL mRNA; the decay rate (half-life) was also inhibited by DA. Consistent with a previous study on turkey pituitary cells (Tong et al. 1998) , VIP significantly increased PRL mRNA half-life from 26·3 h in control cultures to 53·0 h in VIP-treated cells, an effect that was reversed by pre-incubating the cells with the D 2 AG. This is the first time that the inhibitory effect of DA on PRL mRNA stability has been demonstrated in avian or mammalian species. The molecular mechanism(s) by which activation of D 2 DA receptors destabilizes PRL mRNA half-life remains to be clarified. Alterations in one or more of the following mechanisms may be involved: (i) the length of the PRL mRNA poly (A) tail (Diamond & Goodman, 1985 , Jones et al. 1990 ), (ii) the effect on the destabilizing sequence elements, such as AU-rich elements, if they exist (Shaw & Kamen 1986 ), or (iii) the RNA-binding proteins which play a major role in regulating the mRNA half-life (Staton et al. 2000) .
Unlike the inhibitory effect of pituitary D 2 DA receptors, D 1 DA receptor activation showed neither a stimulatory nor inhibitory influence on PRL mRNA expression or release. These results are in agreement with earlier findings from our laboratory (Youngren et al. 1998) . D 1 DA receptors are not found on mammalian pituitary cells (Rovescalli et al. 1987 , Sunahara et al. 1991 . In contrast, three D 1 DA receptor subtypes have been identified and quantified in the turkey pituitary across the reproductive cycle (Schnell et al. 1999 , Chaiseha et al. 2003 .
In conclusion, the present results show, for the first time in an avian species, that DA inhibits VIP-stimulated PRL mRNA at the transcriptional and post-transcriptional (PRL mRNA half-life) levels via pituitary D 2 DA receptors. Camper 
